Trial Profile
A multi-centric, randomized, active controlled parallel group study to evaluate efficacy, tolerability and safety of Adalimumab (Zydus) and Adalimumab (Reference) in patients with Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Cadila Healthcare
- 14 Dec 2013 New trial record